Deccox® and RumensinTM — veterinary medication

Overview

Source: Animal Drugs @ FDA

Proprietary name

Deccox® and RumensinTM

Active ingredient

Decoquinate Monensin

Application type

NADA

Sponsor

Phibro Animal Health Corp.

Applications on record

1

First published

January 28, 2026

Adverse event reports

Source: openFDA VeDDRA

159

Reports mentioning this ingredient

January 27, 1987 – December 18, 2025

50

Classified serious

per reporter assessment

92

Lack of expected efficacy

resistance signal

3

Human operator exposure

needle-stick or splash

Not a risk measure. Veterinary adverse event reports are influenced by how many animals are treated, reporting practice and product age. Reports do not establish that the product caused the event, and a single report can cover an entire herd or flock. Attribution here is by active ingredient because the source dataset redacts brand names.

Attributed by active ingredient “DECOQUINATE”. Green Book ingredient names and VeDDRA ingredient names do not always agree exactly, so attribution is approximate and labelled as such.

Reported reactions

Source: openFDA VeDDRA

Clinical signs coded in the VICH VeDDRA four-level hierarchy, most frequent first.

Reaction terms reported for this ingredient, by report count.
Reaction (VeDDRA term)	Reports	Relative frequency
Lack of efficacy (protozoa) - Coccidia	34
INEFFECTIVE, COCCIDIA	26
Death	21
No sign	21
Hard, clumping	18
Lack of efficacy - NOS	15
Device Defective NOS	8
Seal, Abnormal	5
Overdose	4
Accidental exposure	3
Difficulty of Use	3
Haematochezia	2
Odor, Abnormal	2
Loose stool	2
Contamination NOS	2
Uncoded sign	2
Granules/Powder, Abnormal	2
Color, Abnormal	2
Lack of efficacy (endoparasite) - roundworm NOS	2
UNPALATABLE	2

Species affected

Source: openFDA VeDDRA

Cattle 102 Goat 7 Sheep 7 Chicken 4 Dog 3 Horse 3 Other Birds 2 Cat 1

Regulatory context

New Animal Drug Application (NADA). A pioneer approval evaluated for target animal safety, therapeutic effectiveness, manufacturing controls and — for food-producing species — human food safety including residue depletion.

Extra-label use in food-producing animals is governed by the Animal Medicinal Drug Use Clarification Act of 1994 (AMDUCA) and 21 CFR Part 530. It requires a valid veterinarian-client-patient relationship and is prohibited outright for certain drug classes. Withdrawal times are determined by FARAD, not by this index.

Sources for this page

Animal Drugs @ FDA	FDA CVM	Applications, sponsor, status, withdrawal
Animal & Veterinary Events	FDA CVM	VeDDRA adverse event aggregates by active ingredient